AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

AVECHO BIOTECHNOLOGY LTD

0.004

-0.001-20.00%

Volume:1.31M

Turnover:5.35K

Market Cap:12.68M

PE:-4.00

High:0.005

Open:0.005

Low:0.004

Close:0.005

Loading ...

Overview Company News Filings

Avecho clocks $4.7M payment from pharma giant Sandoz for CBD capsule licence

The Market Herald

Avecho Biotechnology Receives $3 Million Licensing Fee from Sandoz for Cannabidiol Product; Shares Jump 20%

MT Newswires Live

Avecho Biotechnology's 2024 Loss Narrows as Revenue Rises; Shares Fall 14%

MT Newswires Live

Avecho and Sandoz Enter Exclusive License and Development Agreement to Commercialise Cbd for Insomnia in Australia

THOMSON REUTERS

Avecho and Sandoz Enter Exclusive License and Development Agreement to Commercialise Cbd for Insomnia in Australia

THOMSON REUTERS

Avecho and Sandoz enter exclusive license and development agreement to commercialise CBD for insomnia in Australia

Avecho Signs Licensing Agreement with Swiss Off-Patient Medicine Provider

MT Newswires Live

BRIEF-Avecho And Sandoz Enter Exclusive License And Development Agreement

Avecho Biotechnology Ltd - Avecho and Sandoz Enter Exclusive License and Development Agreement to Commercialise Cbd for Insomnia in Australia

THOMSON REUTERS

Avecho Biotechnology Ltd - Avecho to Receive US$3M in Upfront Payment

THOMSON REUTERS

Avecho Biotechnology Full Year 2024 Earnings: AU$0.001 loss per share (vs AU$0.002 loss in FY 2023)

Simply Wall St.

BRIEF-Avecho Biotechnology Seeks Trading Halt Pending Release Of Information About License And Development Agreement

Avecho Biotechnology Ltd - Seeks Trading Halt Pending Release of Information in Relation to Exclusive License and Development Agreement

THOMSON REUTERS

3 Promising ASX Penny Stocks With Over A$10M Market Cap

Simply Wall St.

ASX Biggest Gainers

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/AVE.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AVE.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AVE.AU\",,,,,undefined,":{"symbol":"AVE.AU","market":"AU","secType":"STK","nameCN":"AVECHO BIOTECHNOLOGY LTD","latestPrice":0.004,"timestamp":1745295848774,"preClose":0.005,"halted":0,"volume":1309372,"delay":0,"nameEN":"AVECHO BIOTECHNOLOGY LTD","floatShares":1892229098,"shares":3169297013,"eps":-0.000999,"marketStatus":"Trading","change":-0.001,"latestTime":"04-22 14:44:47 AEST","open":0.005,"high":0.005,"low":0.004,"amount":5349,"amplitude":0.2,"askPrice":0.005,"askSize":10960200,"bidPrice":0.004,"bidSize":17138328,"shortable":3,"etf":0,"ttmEps":-0.000999,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1745301600000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.005,"openAndCloseTimeList":[[1745280000000,1745301600000]],"volumeRatio":4.362641,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AVE.AU\",,,,,undefined,":{"symbol":"AVE.AU","floatShares":1892229098,"roa":"-31.11%","roe":"-64.72%","lyrEps":-0.000985,"volumeRatio":4.362641,"shares":3169297013,"dividePrice":0,"high":0.005,"amplitude":0.2,"preClose":0.005,"low":0.004,"week52Low":0.001,"pbRate":"3.88","psRate":"11.19","week52High":0.009,"institutionHeld":0,"latestPrice":0.004,"committee":0.219874,"eps":-0.000999,"divideRate":0,"volume":1309372,"delay":0,"ttmEps":-0.000999,"open":0.005,"prevYearClose":0.002,"prevWeekClose":0.005,"prevMonthClose":0.005,"prevQuarterClose":0.005,"fiveDayClose":0.005,"twentyDayClose":0.007,"sixtyDayClose":0.003},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AVE.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2522051118","title":"Avecho clocks $4.7M payment from pharma giant Sandoz for CBD capsule licence","url":"https://stock-news.laohu8.com/highlight/detail?id=2522051118","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522051118?lang=en_us&edition=fundamental","pubTime":"2025-03-28 12:46","pubTimestamp":1743137160,"startTime":"0","endTime":"0","summary":"Avecho  has received a US$3 million  payment from pharma heavyweight Sandoz in exchange for the latter’s right to use Avecho’s licence for a CBD capsule sleeping pill.Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.The term ‘CBD’ refers to the non-psychoactive element within marijuana  which has been widely popular in recent years among both medical and recreation markets.CBD is in just about everything from gummy bears, creams and lotions, roll-on sticks, eyedropper bottles, soft drinks, vand apes. The list goes on.But the company stands to make a further US$16M in milestone payments, from Sandoz, should the latter continue progressing Avecho’s CBD capsule product towards commercial sales.The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified fina","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/avecho-clocks-4-7m-payment-from-pharma-giant-sandoz-for-cbd-capsule-licence-2025-03-28/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["ACB","BK4007","CBD","BK4113","AVE.AU","BK7096","BK4557"],"gpt_icon":0},{"id":"2522672593","title":"Avecho Biotechnology Receives $3 Million Licensing Fee from Sandoz for Cannabidiol Product; Shares Jump 20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2522672593","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522672593?lang=en_us&edition=fundamental","pubTime":"2025-03-28 11:49","pubTimestamp":1743133777,"startTime":"0","endTime":"0","summary":"Avecho Biotechnology  received the initial $3 million licensing fee from generic pharmaceuticals company Sandoz for the commercial rights to the former's proprietary cannabidiol  product in Australia, according to a Friday filing with the Australian bourse.Avecho Biotechnology is entitled to receive $16 million upon meeting certain milestones and tiered royalties ranging from 14% to 19% on net sales, per the filing.Under the terms of the agreement, Sandoz has exclusive commercial rights for Avecho's CBD capsule product for insomnia in Australia for 10 years.Avecho Biotechnology's shares jumped 20% in recent trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","AVE.AU","ACB","XKO.AU","CBD","XJO.AU","XAO.AU","BK4557","BK4113","BK7096"],"gpt_icon":0},{"id":"2517140669","title":"Avecho Biotechnology's 2024 Loss Narrows as Revenue Rises; Shares Fall 14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517140669","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517140669?lang=en_us&edition=fundamental","pubTime":"2025-03-07 11:16","pubTimestamp":1741317391,"startTime":"0","endTime":"0","summary":"Avecho Biotechnology  reported Friday that its 2024 loss narrowed to AU$0.001 per diluted share from AU$0.0015 a year earlier.Total revenue for the 12 months ended Dec. 31, 2024, was AU$1.1 million, compared with AU$473,551 a year earlier.The company's shares were down 14% in recent Friday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AVE.AU"],"gpt_icon":0},{"id":"2516569357","title":"Avecho and Sandoz Enter Exclusive License and Development Agreement to Commercialise Cbd for Insomnia in Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2516569357","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516569357?lang=en_us&edition=fundamental","pubTime":"2025-03-04 08:27","pubTimestamp":1741048072,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nTUA5S3SXR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVE.AU","BK7096"],"gpt_icon":0},{"id":"2516661355","title":"Avecho and Sandoz Enter Exclusive License and Development Agreement to Commercialise Cbd for Insomnia in Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2516661355","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516661355?lang=en_us&edition=fundamental","pubTime":"2025-03-04 06:00","pubTimestamp":1741039224,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nTUA5BM02W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVE.AU","BK7096"],"gpt_icon":0},{"id":"2516661616","title":"Avecho and Sandoz enter exclusive license and development agreement to commercialise CBD for insomnia in Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2516661616","media":"PR Newswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516661616?lang=en_us&edition=fundamental","pubTime":"2025-03-04 06:00","pubTimestamp":1741039200,"startTime":"0","endTime":"0","summary":"Avecho and Sandoz sign an exclusive ten-year development and license agreement  for Avecho's pharmaceutical cannabidiol capsule for insomnia in Australia. Avecho to receive upfront, milestone and royalty payments:. US$16M in development milestones prior to commercial sales. Tiered royalties ranging from 14% to 19% on net sales. Sandoz to purchase the product from Avecho for commercial sale. Avecho retains the rights to commercialise the product in all other territories, with Sandoz granted a right of first refusal to exceed any commercial offers Avecho receives. Avecho CEO, Dr Paul Gavin, said: \"We are excited to announce this partnership with Sandoz, which underscores the commercial potential of Avecho's drug delivery platform and our shared commitment to deliver innovative insomnia treatments. Nearly 9.5 million Australians experience symptoms of insomnia with approximately 3.6 million of those considered chronic[3]. Sandoz's extensive reach and expertise in the Australian market wil","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance_au","url":"https://finance.yahoo.com/news/avecho-sandoz-enter-exclusive-license-220000509.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/avecho-sandoz-enter-exclusive-license-220000509.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK4534","BK4588","BK4512","LU1894683264.USD","BK4206","BK4557","LU1093756325.SGD","LU0683600562.USD","XJO.AU","BK4113","BK4585","BK4533","ACB","LU1093756168.USD","CBD","AVE.AU","BK7096","BK4007","LU0787776722.HKD","LU1894683348.USD","MMM","XAO.AU","XKO.AU"],"gpt_icon":0},{"id":"2516088125","title":"Avecho Signs Licensing Agreement with Swiss Off-Patient Medicine Provider","url":"https://stock-news.laohu8.com/highlight/detail?id=2516088125","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516088125?lang=en_us&edition=fundamental","pubTime":"2025-03-03 14:52","pubTimestamp":1740984752,"startTime":"0","endTime":"0","summary":"Avecho Biotechnology  has signed a ten-year exclusive licensing agreement with Switzerland-based Sandoz Group AG for the commercialization of its cannabidiol  capsule aimed at treating insomnia in Australia, according to a Monday filing with the Australian bourse.Under the deal, Avecho will receive an upfront payment of $3 million, milestone payments of up to $16 million, and royalties ranging from 14% to 19% on net sales, the filing said.Avecho will continue funding the ongoing Phase III clinical trial and collaborate with Sandoz on regulatory approval from the Therapeutic Goods Administration, the filing added.Once approved, Sandoz will market and distribute the product in Australia and Avecho will retain commercialization rights in all other territories, with Sandoz holding a right of first refusal, the company said.Shares of the company fell 14% on market close.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CBD","XAO.AU","BK7096","XKO.AU","AVE.AU","BK4113","XJO.AU"],"gpt_icon":0},{"id":"2516046529","title":"BRIEF-Avecho And Sandoz Enter Exclusive License And Development Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2516046529","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516046529?lang=en_us&edition=fundamental","pubTime":"2025-03-03 09:23","pubTimestamp":1740965016,"startTime":"0","endTime":"0","summary":"BRIEF-Avecho And Sandoz Enter Exclusive License And Development Agreement March 3  - Avecho Biotechnology Ltd AVE.AX:AVECHO AND SANDOZ ENTER EXCLUSIVE LICENSE AND DEVELOPMENT AGREEMENT TO COMMERCIALISE CBD FOR INSOMNIA IN AUSTRALIAAVECHO TO RECEIVE US$3M IN UPFRONT PAYMENTFurther company coverage: AVE.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nFWN3PJ27J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVE.AU","BK7096"],"gpt_icon":0},{"id":"2516540220","title":"Avecho Biotechnology Ltd - Avecho and Sandoz Enter Exclusive License and Development Agreement to Commercialise Cbd for Insomnia in Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2516540220","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516540220?lang=en_us&edition=fundamental","pubTime":"2025-03-03 06:47","pubTimestamp":1740955630,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250302:nFWN3PJ27J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVE.AU","BK7096"],"gpt_icon":0},{"id":"2516402295","title":"Avecho Biotechnology Ltd -  Avecho to Receive US$3M in Upfront Payment","url":"https://stock-news.laohu8.com/highlight/detail?id=2516402295","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516402295?lang=en_us&edition=fundamental","pubTime":"2025-03-03 06:47","pubTimestamp":1740955630,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250302:nFWN3PJ27J:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AVE.AU","BK7096"],"gpt_icon":0},{"id":"2516356779","title":"Avecho Biotechnology Full Year 2024 Earnings: AU$0.001 loss per share (vs AU$0.002 loss in FY 2023)","url":"https://stock-news.laohu8.com/highlight/detail?id=2516356779","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516356779?lang=en_us&edition=fundamental","pubTime":"2025-03-02 08:12","pubTimestamp":1740874343,"startTime":"0","endTime":"0","summary":"ASX:AVE Earnings and Revenue History March 2nd 2025. All figures shown in the chart above are for the trailing 12 month  period. Avecho Biotechnology shares are up 17% from a week ago.It is worth noting though that we have found 5 warning signs for Avecho Biotechnology (4 are a bit unpleasant!) that you need to take into consideration.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/avecho-biotechnology-full-2024-earnings-001223573.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["AVE.AU"],"gpt_icon":0},{"id":"2514365761","title":"BRIEF-Avecho Biotechnology Seeks Trading Halt Pending Release Of Information About License And Development Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2514365761","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514365761?lang=en_us&edition=fundamental","pubTime":"2025-02-28 09:32","pubTimestamp":1740706339,"startTime":"0","endTime":"0","summary":"BRIEF-Avecho Biotechnology Seeks Trading Halt Pending Release Of Information About License And Development AgreementFeb 28  - Avecho Biotechnology Ltd AVE.AX:SEEKS TRADING HALT PENDING RELEASE OF INFORMATION IN RELATION TO EXCLUSIVE LICENSE AND DEVELOPMENT AGREEMENTFurther company coverage: AVE.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nFWN3PI1DX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVE.AU","BK7096"],"gpt_icon":0},{"id":"2514556353","title":"Avecho Biotechnology Ltd -  Seeks Trading Halt Pending Release of Information in Relation to Exclusive License and Development Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2514556353","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514556353?lang=en_us&edition=fundamental","pubTime":"2025-02-28 05:53","pubTimestamp":1740693237,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PI1DX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","AVE.AU"],"gpt_icon":0},{"id":"2510152583","title":"3 Promising ASX Penny Stocks With Over A$10M Market Cap","url":"https://stock-news.laohu8.com/highlight/detail?id=2510152583","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510152583?lang=en_us&edition=fundamental","pubTime":"2025-02-12 12:11","pubTimestamp":1739333468,"startTime":"0","endTime":"0","summary":"The Australian stock market has seen modest gains recently, with the ASX200 up 0.25% and sectors like Industrials and Financials showing strong performance. Amidst these movements, the concept of penny stocks remains relevant for investors seeking opportunities in smaller or newer companies that may offer a unique blend of value and growth potential. Despite their somewhat outdated name, penny stocks can still be attractive when backed by solid financials, presenting a chance to uncover hidden value in promising companies.Overview: LaserBond Limited is an Australian surface engineering company focused on improving the performance and longevity of capital-intensive machinery components, with a market cap of A$69.81 million.Operations: The company's revenue is derived from three segments: Products generating","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-promising-asx-penny-stocks-041108064.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["HLO.AU","BK7132","BK7016","BK7055","CAF.AU","BK7070","IGL.AU","EZZ.AU","BK7077","GTN.AU","BK7048","EVO.AU","BK7062","BK7045","PHX.AU","XJO.AU","BK7088","BK7096","XKO.AU","ANG.AU","XAO.AU","AVE.AU","LBL.AU","MXI.AU","SHA.AU"],"gpt_icon":0},{"id":"2500969514","title":"ASX Biggest Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2500969514","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500969514?lang=en_us&edition=fundamental","pubTime":"2025-01-02 09:52","pubTimestamp":1735782724,"startTime":"0","endTime":"0","summary":"Here are the 10 ASX-listed companies with the biggest gains on Friday:Ausmon Resources : +100%, AU$0.0020Eden Innovations : +100%, AU$0.0020Avecho Biotechnology  : +50%, AU$0.0030Lycaon Resources : +50%, AU$0.1350Antilles Gold : +33%, AU$0.0040AuKing Mining : +25%, AU$0.0050Metgasco : +25%, AU$0.0050Hubify : +22%, AU$0.0110OncoSil Medical : +16.7%, AU$0.0070Apollo Minerals : +16.7%, AU$0.0140","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AOA.AU","BK7142","HFY.AU","BK7508","LYN.AU","BK7096","AVE.AU","AAU.AU","BK7104","BK7095","AKN.AU","AON.AU","BK7042","BK7048","OSL.AU","BK7509","EDE.AU","MEL.AU","BK7083"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":15,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AVE.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AVE.AU\",market:\"AU\",,,undefined,":[]}}